Incidence and impact of hospital-acquired pneumonia: a Portuguese nationwide four-year study.

This article presents the incidence of hospital-acquired pneumonia (HAP) in Portugal during a four-year period (2014-2017). Data were retrieved from the 100 Portuguese hospital diagnosis discharge database for adult patients and included gender, age, chronic comorbidities, mortality and hospital length of stay. There were 28,632 episodes of HAP, an incidence of 0.95 per 100 admissions. HAP patients had both a prolonged hospital length of stay (mean 26.4 days) and high mortality (33.6%). Most episodes occurred in patients aged ≥65 years and in males (76.1% and 61.7%, respectively). Invasive ventilation was required in 18.8%.

Impact of antibiotic therapy in severe community-acquired pneumonia: Data from the Infauci study.

Antibiotic therapy (AT) is the cornerstone of the management of severe community-acquired pneumonia (CAP). However, the best treatment strategy is far from being established. To evaluate the impact of different aspects of AT on the outcome of critically ill patients with CAP, we performed a post hoc analysis of all CAP patients enrolled in a prospective, observational, multicentre study. Of the 502 patients included, 76% received combination therapy, mainly a ß-lactam with a macrolide (80%). AT was inappropriate in 16% of all microbiologically documented CAP (n=177). Hospital and 6months mortality were 34% and 35%. In adjusted multivariate logistic regression analysis, combination AT with a macrolide was independently associated with a reduction in hospital (OR 0.17, 95%CI 0.06-0.51) and 6months (OR 0.21, 95%CI 0.07-0.57) mortality. Prolonged AT (>7days) was associated with a longer ICU (14 vs. 7days; p<0.001) and hospital length of stay (LOS) (25 vs. 17days; p<0.001). Combination AT with a macrolide may be the most suitable AT strategy to improve both short and long term outcome of severe CAP patients. AT >7days had no survival benefit and was associated with a longer LOS.

Impact of infection on admission and of the process of care on mortality of patients admitted to the Intensive Care Unit: the INFAUCI study.

A prospective, cohort, clinical, observational study was performed in 14 Intensive Care Units (ICUs) to evaluate the contemporary epidemiology, morbi-mortality and determinants of outcome of the population with an infection on admission. All 3766 patients admitted during a consecutive 12-month period were screened. Their median age was 63 [26-83], 61.1% were male and 69.8% had significant comorbidities. On admission to the ICU 1652 patients (43.9%) had an infection, which was community acquired in 68.2% (one-fifth with healthcare-associated criteria) and ward-acquired in the others. Roughly half presented to the ICU with septic shock. As much as 488 patients with community-acquired infections were deemed stable enough to be first admitted to the ward, but had similar mortality to unstable patients directly admitted to the ICU (35.9% vs. 35.1%, p 0.78). Only 48.3% of this infected population had microbiological documentation and almost one-quarter received inappropriate initial antibiotic therapy. This, along with comorbidities, was a main determinant of mortality. Overall, infected patients on admission had higher mortality both in the ICU (28.0% vs. 19.9%, p <0.001) and in the hospital (38.2% vs. 27.5%, p <0.001) and even after being discharged to the ward (14.2% vs. 9.6%, p <0.001). Also, patients not infected on admission who acquired an infection in the ICU, had an increased risk of dying in the hospital (odds ratio 1.41 [1.12-1.83]). Consequently, infection, regardless of its place of acquisition, was associated with increased mortality. Improving the process of care, especially first-line antibiotic appropriateness, and preventing ICU-acquired infections, may lead to better outcomes.

Acute bacterial meningitis in the intensive care unit and risk factors for adverse clinical outcomes: retrospective study.

BACKGROUND: Bacterial meningitis constitutes a medical emergency. Its burden has driven from childhood to the elderly and the immunocompromised population. However, the admission of patients with bacterial meningitis to the intensive care unit (ICU) has been sparsely approached, as have the prognostic factors associated with an adverse clinical outcome. METHODS: We performed a retrospective analysis during a 7-year period of patients older than 18 years admitted to 2 polyvalent ICUs. Clinical, demographic, and outcome data were collected to evaluate its clinical impact on the outcome of patients with acute bacterial meningitis. RESULTS: We identified 65 patients with the diagnosis of acute bacterial meningitis (mean Acute Physiology and Chronic Health Evaluation II, 23; hospital mortality, 40%). Upon clinical presentation, their most frequent signs were fever (84%), seizures (21.5%), and a low Glasgow Coma Scale (GCS) score (GCS<8; 58.4%). Fifty-five patients (85%) required organ support. A definite microbiological diagnosis was achieved in 45 patients. An adverse clinical outcome was noted in 46 patients (71%). These patients were older (P=.005), had higher Physiology and Chronic Health Evaluation II score (P=.022), and had lower GCS (P=.022). In the multivariate analysis, older age (per year; adjusted odds ratio [aOR], 1.059) was associated with an adverse outcome, whereas a higher GCS (per point; aOR, 0.826) and presence of fever upon admission (aOR, 0.142) increase the chance of a good recovery. CONCLUSIONS: Patients with acute bacterial meningitis admitted to ICU had substantial morbidity and mortality. Those with low GCS or absence of fever have a particularly high risk of an adverse outcome.

Bloodstream infections as a marker of community-acquired sepsis severity. Results from the Portuguese community-acquired sepsis study (SACiUCI study).

The impact of bloodstream infection (BSI) on admission to hospital on the outcome of patients with community-acquired sepsis (CAS) admitted to intensive-care units (ICU) is largely unknown. We selected 803 adult patients consecutively admitted with CAS to one of 17 Portuguese ICU, in whom blood cultures were collected before initiation of antibiotic therapy during a 12-month period. A BSI was identified on hospital admission in 160 (19.9%) patients. Those with and without BSI had similar mean Simplified Acute Physiology Score (SAPS) II and age. The presence of BSI was independently associated with mortality in ICU (adjusted odds ratio 1.86; 95% confidence interval 1.20-2.89; p 0.005). On the 4th day in ICU, patients with BSI were found to be significantly more dependent on vasopressor support (p 0.002) but not on ventilatory support. Cumulative ICU mortality was significantly higher in BSI patients from the 9th day onwards. A seasonal variation of BSI isolates was noted: gram-negative BSI were more common in the summer, whereas in the winter, gram-positive infections were more frequent (p 0.024), without mortality differences.

Community-associated methicillin-resistant Staphylococcus aureus infection in Portugal.

Methicillin-resistant Staphylococcus aureus (MRSA) has recently emerged as a cause of community-acquired infections among individuals without risk factors. Community-associated MRSA (CA-MRSA) appears to be more virulent, causing superficial mild skin and soft tissue infections to severe necrotizing fasciitis, and in rare cases, pneumonia. Community-associated MRSA was first reported in Australia in the early 80s, after almost two decades in the USA, and then in several countries in Europe, Asia and South America. No data exists in Portugal. We report the first case of CA-MRSA infection in Portugal, in a young adult with severe necrotizing pneumonia, complicated with bilateral empyema and respiratory failure.

Pharmacokinetics of gentamicin in critically ill patients: pilot study evaluating the first dose.

Gentamicin is extensively used in the treatment of severe Gram-negative bacterial infections. A loading dose of 7 mg/kg is recommended to achieve a maximum concentration (C(max)) above 16 mg/L. We studied gentamicin pharmacokinetic data from patients treated between January 2006 and June 2008 in two intensive-care units. The Sawchuk and Zaske one-compartment pharmacokinetic model was used to estimate the gentamicin volume of distribution (the 32 patients had a median age of 68 years (23 men)). The median volume of distibution (V(d)) per kilogram of body weight (V(d)/kg) was 0.41 L/kg (interquartile range of 0.36-0.46 L/kg), with no correlations with age, Charlson comorbidity score, sequential organ failure assessment (SOFA) score and creatinine serum level (r(2) = 0.016, 0.058, 0.037, and 0.067, respectively). Women had a significantly higher median V(d)/kg (0.50 vs. 0.40 L/kg, p 0.002) and lower C(max) (15.2 vs. 18.5 mg/L, p 0.016), despite similar dose/kg. In a logistic regression model, only sex (female: OR 0.032; 95% CI 0.03-0.387) and dose/kg (per mg/kg: OR 3.21; 95% CI 1.17-8.79) were significantly associated with the achievement of C(max) above 16 mg/L. Gentamicin clearance was 57 mL/min (interquartile range of 44.7-78 mL/min) and decreased with age (r(2) = 0.178, p 0.016), SOFA score (r(2) = 0.199, p 0.011) and creatinine clearance (r(2) = 0.258, p 0.003). Gentamicin V(d) was increased in critically ill patients, particularly in women. Therefore, high gentamicin loading doses should be given to all patients, especially women, independently of organ failure. Gentamicin clearance decreases with age, SOFA score, and renal failure.